1. LLY uses GLP-1 success to fund research into major unmet health challenges. 2. The company is testing Kisunla to potentially prevent Alzheimer's disease. 3. Lilly is investing in gene therapy and innovative drug delivery systems. 4. Record growth from Mounjaro underpins a market cap of $823 billion.
LLY’s diversification leveraging GLP-1 profits positions it for further revenue streams. Historical examples show that major pipeline advancements can translate into significant long-term stock uplift.
The article outlines strategic investments that could reshape LLY’s future revenue despite longer development timelines, making it highly impactful for the stock.
The investments in Alzheimer’s prevention and gene therapy require extended development and regulatory approval. Past pharmaceutical breakthroughs often take time to materialize but yield strong long-term benefits.